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Abstract
Background: Virtual histology intravascular ultrasound (VH-IVUS) imaging is an innovative tool for the morphological
evaluation of coronary atherosclerosis. Evidence for the effects of statin therapy on VH-IVUS parameters have been
inconclusive. Consequently, we performed a systematic review and meta-analysis to investigate the impact of statin
therapy on plaque volume and its composition using VH-IVUS.
Methods: The search included PubMed, Cochrane Library, Scopus and Embase (through 30 November 2014) to
identify prospective studies investigating the effects of statin therapy on plaque volume and its composition
using VH-IVUS.
Results: We identified nine studies with 16 statin treatment arms and 830 participants. There was a significant
effect of statin therapy in reducing plaque volume (standardized mean difference (SMD): −0.137, 95 % confidence
interval (CI): −0.255, −0.019; P = 0.023), external elastic membrane volume (SMD: −0.097, 95 % CI: −0.183, −0.011;
P = 0.027) but not lumen volume (SMD: −0.025, 95 % CI: −0.110, +0.061; P = 0.574). There was a significant
reduction in fibrous plaque volume (SMD: −0.129, 95 % CI: −0.255, −0.003; P = 0.045) and an increase of dense
calcium volume (SMD: +0.229, 95 % CI: +0.008, +0.450; P = 0.043), while changes in fibro-fatty (SMD: −0.247, 95 %
CI: −0.592, +0.098; P = 0.16) and necrotic core (SMD: +0.011, 95 % CI: −0.144, +0.165; P = 0.892) tissue volumes
were not statistically significant.
Conclusions: This meta-analysis indicates a significant effect of statin therapy on plaque and external elastic
membrane volumes and fibrous and dense calcium volumes. There was no effect on lumen volume, fibro-fatty
and necrotic tissue volumes.
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Background
Despite continuously improving therapies used for acute
coronary syndromes (ACS), cardiovascular disease
(CVD) and its complications remain the leading causes
of mortality and morbidity [1]. The most important
mechanism leading to ACS is the rupture of a vulnerable
plaque and subsequent thrombus formation [2–4]. The
lesion most frequently prone to rupture is represented
by the thin-cap fibroatheroma (TCFA), which contains a
large necrotic core with an overlying thin fibrous cap
[5]. The recently introduced technique of virtual
histology intravascular ultrasound (VH-IVUS) utilizes
spectral analysis of the radiofrequency ultrasound back-
scatter signals, which allows in vivo differentiation of
four distinct atherosclerotic plaque phenotypes: fibrous;
fibro-fatty; dense calcium; and necrotic core [6]. In vivo
studies of coronary [7] and carotid plaques [8] have
demonstrated the accuracy of VH-IVUS for histological
characterization of atherosclerotic plaques.
The Providing Regional Observations to Study Predictors
of Events in the Coronary Tree (PROSPECT), the
VH-IVUS in Vulnerable Atherosclerosis (VIVA) and
the European Collaborative Project on Inflammation
and Vascular Wall Remodeling in Atherosclerosis
(ATHEROREMO-IVUS) substudy are three important
prospective studies that have demonstrated that the
presence of VH-IVUS-derived TCFA lesions is strongly
and independently predictive for the occurrence of major
adverse cardiovascular events (MACE) [9–11]. Extensive
research has focused on preventing CVD events, includ-
ing therapies that may stabilize atherosclerotic plaques
[12]. There is a well-established association between ther-
apy with high doses of statins and regression of coronary
atherosclerosis [13]. Also, there have been studies that
have investigated the efficiency of statin therapy on cor-
onary plaque composition evaluated with the VH-IVUS
method [14, 15]. However, these studies were conducted
in relatively small study cohorts and are not conclusive.
It is not established whether and to what extent statins
have an effect on coronary plaque composition. The
purpose of this meta-analysis was therefore to investi-
gate the impact of statin therapy on coronary plaque
composition.
Methods
Data sources
This study was designed according to the guidelines of
the 2009 Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) statement [16].
Our search included Scopus, Medline, Web of Science
and Cochrane Library databases. It was limited to pro-
spective studies carried out up to 30 November 2014, in-
vestigating the potential effects of statin therapy on
plaque volume and its composition. The databases were
searched using the following search terms in titles and
abstracts (also in combination with Medical Subject
Headings (MeSH) terms): ‘virtual histology intravascular
ultrasound’ OR ‘virtual histology IVUS’ OR ‘VH IVUS’
OR ‘VH-IVUS’ AND ‘statins’ (all fields) OR ‘statin’ (all
fields) OR ‘statin therapy’ (all fields) OR ‘rosuvastatin’
OR ‘pravastatin’ OR ‘fluvastatin’ OR ‘simvastatin’ OR
‘atorvastatin’ OR ‘pitavastatin’ OR ‘lovastatin’ OR
‘cerivastatin’ AND ‘virtual histology intravascular ultra-
sound’ (all fields) OR ‘virtual histology IVUS’ (all fields)
OR ‘VH IVUS’ (all fields) OR ‘VH-IVUS’ (all fields). The
wild-card term ‘*’ was used to increase the sensitivity of
the search strategy. No language restriction was used in
the literature search. The search was limited to studies
in humans. References of all obtained articles were add-
itionally explored for supplemental publications. Two re-
viewers (CS and AS) examined every article separately to
minimize the possibility of duplication, investigating
reviews, case studies and experimental studies. Dis-
agreements were managed by discussion with a third
party (MB).
Study selection
Inclusion criteria
Original studies were included if they met the following
inclusion criteria: a) being a prospective clinical study;
b) investigating the impact of statin therapy on plaque
volume and/or its composition using VH-IVUS (in
comparison to placebo group or high-intensity versus
moderate/low-intensity statin therapy); c) presentation
of sufficient information on VH-IVUS findings at base-
line and at the end of study; and d) statin therapy for
at least 2 weeks.
Exclusion criteria
Exclusion criteria were: a) non-clinical studies (experi-
mental and basic studies); b) observational or retrospect-
ive studies; c) duplicate reports or secondary or post hoc
analyses of the same study population; and d) lack of
sufficient information on baseline or follow-up VH-
IVUS data. Exclusion of an article for this reason was
also done if no feedback was received after contacting
the author(s).
Data extraction
Eligible studies were reviewed and the following data
were abstracted: 1) first author’s name; 2) year of publi-
cation; 3) study location; 4) number of participants;
5) age, gender and body mass index (BMI) of study
participants; 6) baseline levels of total cholesterol (TC),
low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), triglycerides (TG),
high-sensitivity C-reactive protein (hs-CRP) and glucose;
7) systolic (SBP) and diastolic blood pressure (DBP);
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8) statin type, statin dose and duration of treatment
(both in research and control groups); and 9) data
regarding baseline and follow-up VH-IVUS findings
including plaque volume (PV), lumen volume (LV), exter-
nal elastic membrane volume (EEMV), as well as ather-
oma compositional data (comprising volumes of fibrous,
fibro-fatty, dense calcium and necrotic core tissues).
Quality assessment and quantitative data synthesis
The quality of included studies was assessed using the
Cochrane scale. Meta-analysis was conducted using
Review Manager, version 5.2 (Cochrane Collaboration,
Oxford, UK), and Comprehensive Meta-Analysis (CMA)
V2 software (Biostat, NJ, USA) [17]. Standard deviations
(SD) of the mean difference were calculated using the
following formula: SD = square root ((SDpre-treatment)
2 +
(SDpost-treatment)
2 − (2R × SDpre-treatment × SDpost-treatment)),
assuming a correlation coefficient (R) = 0.5. In case of
reporting SEM, SD was estimated using the following for-
mula: SD = SEM × sqrt (n), where n is the number of sub-
jects. In case levels were reported as the median and
interquartile range, the mean and SD were estimated using
the recommendations of Hozo et al. [18].
Net changes in measurements (change scores) were
calculated for parallel and crossover trials, as follows:
measure at end of follow-up − measure at baseline.
A random-effects model (using DerSimonian–Laird
method) and the generic inverse variance method
were used to compensate for the heterogeneity of
studies in terms of statin type, statin dose, study design,
treatment duration and the characteristics of populations
being studied [19]. Effect sizes were expressed as weighed
standardized mean difference (SMD) and 95 % confi-
dence intervals (CI). In order to evaluate the influence of
each study on the overall effect size, sensitivity analysis
was conducted using the one-study remove (leave-one-
out) approach.
Meta-regression
Meta-regression was performed using a random-effects
model (using unrestricted maximum likelihood method)
to evaluate the association between calculated SMD in
plaque volume with duration of statin therapy and
changes in LDL-C concentrations.
Publication bias
Potential publication bias was explored using visual in-
spection of Begg’s funnel plot asymmetry, and Begg’s
rank correlation and Egger’s weighted regression tests.
The Duval and Tweedie ‘trim and fill’ and ‘fail-safe N’
Fig. 1 Flow diagram for study selection. VH-IVUS, virtual histology intravascular ultrasound
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Table 1 Demographic characteristics of the included studies
Study Eshtehardi et al. [21] Guo et al. [22] Hong et al. [23] Hwang et al. [24] Lee et al. [14]
Year 2012 2012 2009 2013 2012
Location USA China Korea Korea Hong Kong
Design Pilot study on consecutive
patients treated with
atorvastatin
Randomized placebo-controlled
parallel group trial
Randomized parallel
group trial
Prospective study on
patients treated with
statin
Prospective randomized
double-blind parallel
group trial
Duration of study 6 months 6 months 12 months 6 months 6 months
Inclusion criteria Patients with an abnormal
non-invasive stress test, stable
angina or stabilized acute
coronary syndrome who were
found to have moderate lesions
requiring invasive physiologic
evaluation
Coronary heart disease patients
with stable atherosclerotic
plaques
Patients with de novo non-culprit/
non-target lesions without
significant stenosis by coronary
angiogram (diameter stenosis
<50 %), lesions with a plaque
burden <0.75 by gray-scale IVUS,
and lesions located in 1 of 3
major epicardial arteries in which
stent implantation was not
performed
Patients with acute
coronary syndrome
Statin-naive patients free from
unstable angina >8 weeks
before intervention or acute
coronary syndrome and with
angiographic critical coronary
stenosis requiring percutaneous
coronary intervention
Statin form Atorvastatin Atorvastatin Simvastatin or rosuvastatin NS Atorvastatin
Statin intervention 80 mg/day 10–80 mg/day 20 mg/day or 10 mg/day NS 10–40 mg/day
Participants Intervention 20 47a 50e 54 19a
45b
43c 50f 20c
39d
Control - 54 - - -
Age (years) Intervention 54 (46–68) 62.64 ± 12.0a 58 ± 10e 59 ± 10 65.05 ± 9.99a
59.18 ± 8.48b
58.91 ± 12.90c 59 ± 9f 63.70 ± 9.80c
58.95 ± 9.68d
Control - 62.07 ± 8.51 - - -
Male (%) Intervention 65.0 88.88a 80.0e 70.37 73.68a
85.10b
80.0c 74.0f 90.0c
95.35d
Control - 87.18 - - -
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Table 1 Demographic characteristics of the included studies (Continued)
BMI (kg/m2) Intervention 30 (27–36) NSa NSe NS 26.83 ± 6.85a
NSb
NSc NSf 26.58 ± 5.44c
NSd
Control - NS - - -
hs-CRP (mg/L) Intervention NS 6.04 ± 2.52a 0.17 ± 0.22e 3.18 ± 5.29 NSa
5.09 ± 1.94b
5.67 ± 2.22c 0.21 ± 0.20f NSc
6.10 ± 2.12d
Control - 5.07 ± 1.80 - - -
Total cholesterol (mg/dL) Intervention 186.0 (168.0–212.5) NSa 191 ± 34e 195.0 ± 35.9 200.58 ± 41.54a
NSb
NSc 189 ± 27f 184.17 ± 29.27c
NSd
Control - NS - - -
LDL-C (mg/dL) Intervention 118.5 (105.3–140.5) 116.96 ± 27.02a 119 ± 30e 119.7 ± 31.4 122.39 ± 39.54a
112.71 ± 23.93b
111.94 ± 13.12c 116 ± 28f 112.35 ± 27.14c
109.24 ± 25.48d
Control - 113.48 ± 27.79 - - -
HDL-C (mg/dL) Intervention 39.5 (33.3–52.8) 34.74 ± 6.56a 43 ± 10e 38.9 ± 8.5 41.47 ± 9.46a
35.90 ± 7.72b
37.44 ± 9.26c 43 ± 11f 42.82 ± 17.45c
34.74 ± 5.02d
Control - 37.06 ± 6.95 - - -
Triglycerides (mg/dL) Intervention 115.5 (83.5–158.8) NSa 149 ± 69e 178.5 ± 126.1 168.58 ± 96.19a
NSb
NSc 152 ± 75f 154.42 ± 1.02c
NSd
Control - NS - - -
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Table 1 Demographic characteristics of the included studies (Continued)
Glucose (mg/dL) Intervention NS 103.14 ± 18.0a NSe NS NSa
102.96 ± 14.76b
90.0 ± 14.94c NSf NSc
101.34 ± 17.46d
Control - 94.68 ± 17.64 - NS -
SBP (mmHg) Intervention 129 (114–145) NSa NSe NS NSa
NSb
NSc NSf NSc
NSd
Control - NS - - -
DBP (mmHg) Intervention 72 (68–83) NSa NSe NS NSa
NSb
NSc NSf NSc
NSd
Control - NS - - -
Plaque volume (mm3) Intervention 308.8 (236.8–432.6) 38.07 ± 13.94a 88.3 ± 26.9e 76.1 ± 32.1 98.47 ± 70.84a
33.83 ± 10.56b
37.06 ± 12.01c 91.5 ± 27.5f 144.17 ± 154.46c
36.47 ± 14.68d
Control - 34.83 ± 13.76 - - -
Lumen volume (mm3) Intervention 427.3 (310.9–703.7) NSa 85.2 ± 20.4e 70.5 ± 24.1 NSa
NSb
NSc 87.6 ± 26.2f NSc
NSd
Control - NS - - -
External elastic membrane
volume (mm3)
Intervention 830.9 (606.8–1,080.1) NSa 173.5 ± 37.1e 146.6 ± 52.3 NSa
NSb
NSc 179.1 ± 46.6f NSc
NSd
Control - NS - - -
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Table 1 Demographic characteristics of the included studies (Continued)
Fibrous volume (mm3) Intervention 89.9 (67.1–123.9) NSa 25.6 ± 12.7e 27.7 ± 15.6 37.04 ± 30.41a
NSb
NSc 28.2 ± 14.4f 54.90 ± 58.05c
NSd
Control - NS - - -
Fibro-fatty volume (mm3) Intervention 10.6 (6.4–27.9) NSa 4.1 ± 2.9e 4.5 ± 3.9 9.76 ± 9.80a
NSb
NSc 4.5 ± 4.0f 19.39 ± 36.04c
NSd
Control - NS - - -
Dense calcium volume (mm3) Intervention 10.5 (4.0–20.9) NSa 6.5 ± 6.3e 4.2 ± 3.2 3.18 ± 3.44a
NSb
NSc 6.8 ± 6.4f 4.85 ± 7.68c
NSd
Control - NS - - -
Necrotic core volume (mm3) Intervention 30.8 (13.9–48.2) NSa 15.8 ± 11.3e 8.7 ± 6.4 7.91 ± 7.47a
NSb
NSc 15.5 ± 8.4f 11.89 ± 18.72c
NSd
Control - NS - - -
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Table 1 Demographic characteristics of the included studies (Continued)
Study Nasu et al. [25] Nozue et al. [26] Puri et al. [27] Taguchi et al. [28]
Year 2009 2012 2014 2013
Location Japan Japan USA Japan
Design Prospective and multicenter
study with non-randomized
and no blinded design
Prospective, open-labeled, randomized,
multicenter study
Randomized parallel-group trial Prospective, non-randomized, non-controlled
and open-label trial
Duration of study 12 months 8 months 24 months 8–10 months
Inclusion criteria Patients older than 30 years
of age with symptomatic
stable angina pectoris.
Angiographic inclusion
criteria: 1) target vessel for
VH-IVUS interrogation must
not have undergone
angioplasty or have more
than 50 % luminal narrowing
throughout a target segment
with a minimum length of
30 mm; 2) target vessel for
VH-IVUS interrogation had
mild-to-moderate vessel
tortuosity and calcification
for safe and accurate
examination; and 3) left
ventricular ejection fraction
>30 %
Patients with stable and unstable
angina after successful percutaneous
coronary intervention
Patients with angiographically
demonstrable coronary disease
and LDL-C <116 mg/dL,
following a 2-week treatment
period with atorvastatin
(40 mg) or rosuvastatin
(20 mg) daily
Patients with acute coronary syndrome
defined as unstable angina of Braunwald
class IIIB (angina at rest without increased
levels of the creatine kinase-MB fraction
within 24 hours before coronary
angiography), non-ST-segment elevation
myocardial infarction, or ST-segment
elevation myocardial infarction
Statin form Fluvastatin Pitavastatin or pravastatin Rosuvastatin or atorvastatin Atorvastatin or pitavastatin
Statin intervention 60 mg/day 4 mg/day or 20 mg/day 40 mg/day or 80 mg/day 10 mg/day or 2 mg/day
Participants 40 58g 36i 60a
61h 35d 60j
39 - -
Age (years) 63 ± 10 66 ± 9g 57.6 ± 9.0** 65.8 ± 16.2#
67 ± 11h 63.7 ± 16.5##
62 ± 12 - - -
Male (%) 80.0 89.65g 80.3** 76.6#
77.05h 69.2##
77.5 - - -
BMI (kg/m2) NS 24.4 ± 3.5g 28.6 ± 4.5** 24.0 ± 2.5#
24.5 ± 3.3h 24.2 ± 2.7##
NS - - -
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Table 1 Demographic characteristics of the included studies (Continued)
hs-CRP (mg/L) 2.05 ± 2.20 3.76 (1.22–9.22)g 1.4 (0.7–2.7)** NS#
4.23 (1.21–9.26)h NS##
1.19 ± 1.03 - - -
Total cholesterol (mg/dL) 239.1 ± 32.8 199 ± 34g 203.1 ± 38** NS#
210 ± 38h NS##
199.5 ± 22.8 - - -
LDL-C (mg/dL) 144.9 ± 31.5 126 ± 28g 128.6 ± 30.7** 117.3 ± 34.7#
137 ± 35h 116.2 ± 26.7##
122.3 ± 18.9 - - -
HDL-C (mg/dL) 52.7 ± 12.4 46 ± 11g 44.7 ± 11.0** 46.8 ± 10.9#
47 ± 11h 46.5 ± 11.4##
54.3 ± 17.8 - - -
Triglycerides (mg/dL) 200.6 ± 125.4 129 ± 73g 130 (99–191)** 115.6 ± 22.6#
134 ± 58h 119.9 ± 35.2##
122.8 ± 50.1 - -
Glucose (mg/dL) NS NSg NS** NS#
NSh NS##
NS - - -
SBP (mmHg) NS NSg NS** NS#
NSh NS##
NS - - -
DBP (mmHg) NS NSg NS** NS#
NSh NS##
NS - - -
Plaque volume (mm3) 440.2 ± 220.3 9.06 ± 2.90g* 146.0 ± 55.6** 10.2 ± 3.0#*
8.83 ± 3.67h* 9.9 ± 2.9##*
432.9 ± 247.5 - - -
Lumen volume (mm3) 373.7 ± 188.4 7.40 ± 2.55g* 214.9 ± 71.5** 6.6#*§
7.42 ± 2.66h* 8.0 ± 2.8##*
444.7 ± 233.5 - - -
External elastic membrane
volume (mm3)
813.9 ± 398.5 16.46 ± 4.98g* 360.9 ± 108.8** 16.8 ± 4.6#*
16.25 ± 5.63h* 17.9 ± 5.0##*
877.6 ± 458.3 - - -
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Table 1 Demographic characteristics of the included studies (Continued)
Fibrous volume (mm3) 146.5 ± 85.6 3.46 ± 1.65g* 18.5 (9.8–29.3)** 5.9 ± 2.6#*
3.13 ± 1.98h* 5.8 ± 2.3##*
142.9 ± 113.3 - - -
Fibro-fatty volume (mm3) 80.1 ± 57.9 1.09 ± 0.88g* 23.1 (8.8–36.3)** 1.5 ± 1.1#*
1.05 ± 1.03h* 0.7 ± 0.6##*
50.7 ± 32.9 - - -
Dense calcium volume (mm3) 9.4 ± 9.9 0.42 ± 0.35g* 1.2 (0.2–3.8)** 0.6#*§
0.44 ± 0.47h* 0.6##*§
13.7 ± 12.7 - - -
Necrotic core volume (mm3) 21.4 ± 24.9 0.68 ± 0.42g* 5.9 (2.6–12.3)** 1.6 ± 0.9#*
0.80 ± 0.66h* 2.1 ± 1.4##*
22.1 ± 17.4 - - -
Values are expressed as mean ± SD or median (25–75 percentiles). a10 mg/day atorvastatin arm; b20 mg/day atorvastatin arm; c40 mg/day atorvastatin arm; d80 mg/day atorvastatin arm; e20 mg/day simvastatin arm;
f10 mg/day rosuvastatin arm; g4 mg/day pitavastatin arm; h20 mg/day pravastatin arm; i40 mg/day rosuvastatin arm; j2 mg/day pitavastatin arm; *the value was provided as volume index defined as the volume divided by the
segment length (mm3/mm); **the value was provided for rosuvastatin and atorvastatin arms together; #patients belonging to plaque regression group (n = 94); ##patients belonging to plaque progression (n = 26) group; §SD
not shown. BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; IVUS, intravascular ultrasound; LDL-C, low-density lipoprotein cholesterol;
MB, myocardial band; NS, not stated; SBP, systolic blood pressure; VH-IVUS, virtual histology intravascular ultrasound
Banach
et
al.BM
C
M
edicine
 (2015) 13:229 
Page
10
of
20
methods were used to adjust the analysis for the effects
of publication bias [20].
Results
Search results and trial flow
A total of nine eligible studies comprising 16 treatment
arms met the inclusion criteria and were included for
the final meta-analysis [14, 21–28]. An overview of the
study selection process is presented in Fig. 1.
Characteristics of included studies
Among 830 participants in the included studies, 737
were allocated to statin intervention groups (with differ-
ent statin preparations and different doses) and 93 to
placebo group. The number of participants in these
studies ranged from 20 to 228. The studies were pub-
lished between 2009 and 2014, and were conducted in
USA (two studies), South Korea (two studies), China,
Hong Kong and Japan (three studies). The following
statin doses were administered in the included trials: 10
to 80 mg/day atorvastatin; 10 to 40 mg/day pravastatin;
20 mg/day simvastatin; 10 to 40 mg/day rosuvastatin;
60 mg/day fluvastatin; and 2 to 4 mg/day pitavastatin.
One study did not mention statin preparation or dos-
age [24]. Duration of statin intervention ranged from
6 to 24 months. Only two studies were placebo-
controlled, the other seven included only statin inter-
vention groups. Demographic and baseline parameters
of the included studies are shown in Table 1.
Risk of bias assessment
According to the Cochrane Collaboration [29], a specific
tool for assessing risk of bias in every study involved
consists of selection of particular characteristics of the
study. This involves assessing the risk of bias as ‘low
risk’, ‘high risk or ‘unclear risk’. The last category reveals
either lack of detail or concern over the potential for
bias. There are seven examined fields including: se-
quence generation (selection bias); allocation sequence
concealment (selection bias); blinding of participants
and personnel (performance bias); blinding of outcome
assessment (detection bias); incomplete outcome data
(attrition bias); selective outcome reporting (reporting
bias); and other potential sources of bias (Table 2).
Quantitative data synthesis
Meta-analysis of data from 16 statin-treated arms
showed a significant effect of statin therapy in reducing
plaque volume (SMD: −0.137, 95 % CI: −0.255, −0.019;
P = 0.023) (Fig. 2). This effect size was robust in the
sensitivity analysis and remained at a significant or
borderline significant levels following omission of each
single study (Fig. 3). Statin therapy was also associ-
ated with a significant decrease in EEMV (SMD: −0.097,
95 % CI: −0.183, −0.011; P = 0.027) but not LV
(SMD: −0.025, 95 % CI: −0.110, +0.061; P = 0.574)
(Fig. 2).
The analysis of plaque composition data indicated
significant reduction in fibrous (SMD: −0.129, 95 %
CI: −0.255, −0.003; P = 0.045) and increase in dense
calcium (SMD: 0.229, 95 % CI: 0.008, 0.450; P = 0.043) vol-
umes, while fibro-fatty (SMD: −0.247, 95 % CI: −0.592,
+0.098; P = 0.160) and necrotic core (SMD: 0.011, 95 %
CI: −0.144, +0.165; P = 0.892) tissue volumes remained
statistically unaltered (Fig. 4).
A subgroup analysis was performed to compare the
impact of high-intensity versus moderate/low-intensity
statin therapy on coronary atherosclerosis according
to American College of Cardiology (ACC)/American
Heart Association (AHA) lipid guidelines [30]. High-
intensity statin therapy had a greater effect in reducing
plaque volume (SMD: −0.338, 95 % CI: −0.637, −0.040;
P = 0.026) compared with moderate/low-intensity treat-
ment (SMD: −0.071, 95 % CI: −0.167, +0.026; P = 0.152)
Table 2 Assessment of risk of bias in the included studies using Cochrane criteria
Study Reference Sequence
generation
Allocation
concealment
Blinding of
participants
and personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
outcome
reporting
Other potential
threats to validity
Eshtehardi et al. 2012 [21] H H H H L L L
Guo et al. 2012 [22] U U H H L L L
Hong et al. 2009 [23] U U H H L L L
Hwang et al. 2013 [24] H H H L L L H
Lee et al. 2012 [14] L L L L L L L
Nasu et al. 2009 [25] H H H H L L L
Nozue et al. 2012 [26] L L H L L L L
Puri et al. 2014 [27] U U H H L L L
Taguchi et al. 2013 [28] H H H H L L L
H, high risk of bias; L, low risk of bias; U, unclear risk of bias
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Fig. 2 Forest plot detailing weighted mean difference and 95 % confidence intervals for the impact of statin therapy on plaque, lumen and
external elastic membrane volumes according to virtual histology intravascular ultrasound (VH-IVUS). Meta-analysis was performed using a
random-effects model with inverse variance weighting
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(Fig. 5). However, no significant difference between the
subgroups was observed in terms of effects on LV and
EEMV (Fig. 5). With respect to plaque composition
parameters, significant changes in dense calcium
(SMD: 0.091, 95 % CI: 0.011, 0.171; P = 0.025) and fibrous
(SMD: −0.399, 95 % CI: −0.722, −0.076; P = 0.015)
volumes were observed in the moderate/low-intensity
and high-intensity subgroups, respectively (Fig. 6).
The effects of both treatment regimens on fibro-fatty
and necrotic core tissue volumes were statistically
comparable (Fig. 6).
Another subgroup analysis was performed to compare
the effects of statin therapy on coronary atherosclerosis in
the subgroups of trials with and without ACS patients. PV
Fig. 3 Leave-one-out sensitivity analysis of the impact of statin therapy on plaque volume
Fig. 4 Forest plot detailing weighted mean difference and 95 % confidence intervals for the impact of statin therapy on plaque composition
parameters according to virtual histology intravascular ultrasound (VH-IVUS). Meta-analysis was performed using a random-effects model with
inverse variance weighting
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Fig. 5 Forest plot detailing weighted mean difference and 95 % confidence intervals for the impact of high-intensity versus moderate/low-intensity
statin therapy on plaque, lumen and external elastic membrane volumes according to virtual histology intravascular ultrasound (VH-IVUS). Meta-analysis
was performed using a random-effects model with inverse variance weighting
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was reduced only in the subset of trials not recruiting
ACS patients (SMD: −0.175, 95 % CI: −0.334, −0.015;
P = 0.032). The impact of statin therapy on other indices
in ACS+ and ACS− subgroups are summarized in Table 3.
Meta-regression
Meta-regression analysis was conducted to assess the
association between statin-induced changes in PV with dur-
ation of statin therapy and respective changes in plasma
LDL-C concentrations as potential confounders. In meta-
regression analysis, the impact of statins on PV was found
to be independent of treatment duration (slope: 0.00007; 95
% CI: −0.006, +0.006; P = 0.980). Likewise, statin-induced
reduction in PV was not found to be significantly associated
with LDL-C reductions (slope: −0.002; 95 % CI: −0.015,
+0.011; P = 0.788) (Fig. 7). Further analyses did not
reveal any significant association between statin-
induced changes in PV and other potential con-
founders including age, dose (atorvastatin), age, pro-
portion of males, proportion of diabetics, proportion
of smokers and baseline LDL-C (Table 4).
Publication bias
The results of Egger’s linear regression (intercept = 0.860,
standard error = 1.866; 95 % CI: −3.142, +4.861, t = 0.461,
df = 14.00; two-tailed P = 0.652) and Begg’s rank correl-
ation (Kendall’s tau with continuity correction = 0.025,
Z = 0.135; two-tailed P = 0.893) tests did not provide
any proof of significant publication bias for the de-
creasing effect of statin therapy on PV. However, the
funnel plot of precision (1/standard error) by effect
size (SMD) was found to be asymmetric and suggest-
ive of potential publication bias. The observed publica-
tion bias was imputed using trim-and-fill correction.
Fig. 6 Forest plot detailing weighted mean difference and 95 % confidence intervals for the impact of high-intensity versus moderate/low-intensity
statin therapy on plaque composition parameters according to virtual histology intravascular ultrasound (VH-IVUS). Meta-analysis was performed using
a random-effects model with inverse variance weighting
Table 3 Comparison of the effects of statin therapy on coronary atherosclerosis indices in subgroups of trials recruiting subjects
with and without ACS
Without ACS With ACS
SMD 95 % CI P value SMD 95 % CI P value
Plaque volume −0.175 −0.334, −0.015 0.032 −0.080 −0.258, 0.099 0.382
Lumen volume −0.033 −0.121, 0.056 0.469 −0.007 −0.148, 0.134 0.919
External elastic membrane volume (mm3) −0.065 −0.154, 0.024 0.150 −0.121 −0.263, 0.020 0.093
Fibrous volume (mm3) −0.010 −0.053, 0.133 0.888 0.027 −0.243, 0.297 0.844
Fibro-fatty volume −0.395 −0.824, 0.034 0.071 0.008 −0.312, 0.328 0.961
Dense calcium volume −0.119 −0.304, 0.065 0.206 −0.137 −0.266, −0.007 0.038
Necrotic core volume 0.271 −0.013, 0.555 0.062 0.074 −0.055, 0.203 0.261
ACS, acute coronary syndrome; CI, confidence interval; SMD, standardized mean difference
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This correction suggested no asymmetry on the right of the
mean, while five potentially missing studies were imputed on
the left of the mean leading to a corrected effect size that
was significant: SMD: −0.232 (95 % CI: −0.351, −0.114). The
‘fail-safe N’ method indicated that 38 theoretically missing
studies would need to be added to the analysis before the
overall effect size becomes trivial. Funnel plot of the impact
of statins on plaque volume is illustrated in Fig. 8.
Discussion
The present systematic review and meta-analysis provides
a comprehensive assessment of the impact of statin therapy
Fig. 7 Random effects meta-regression plots of the association between mean changes in plaque volume with treatment duration, and changes
in plasma low-density lipoprotein cholesterol (LDL-C) concentrations. The size of each circle is inversely proportional to the variance of change.
Meta-regression was performed using unrestricted maximum likelihood method
Table 4 Impact of potential confounders on changes in plaque
volume following statin therapy in random-effects meta-regression
Confounder Slope 95 % CI P value
Age (years) 0.009 −0.020, 0.039 0.537
% Males −0.011 −0.024, 0.002 0.106
% Diabetics 0.003 −0.002, 0.008 0.255
% Smokers −0.004 −0.009, 0.0004 0.075
Dose (mg/day)a −0.007 −0.015, 0.001 0.091
Baseline LDL-C (mg/dL) 0.004 −0.007, 0.016 0.435
aRestricted to atorvastatin trials. CI, confidence interval; LDL-C, low-density
lipoprotein cholesterol
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on coronary plaque composition assessed with VH-IVUS.
We observed a significant effect of statin therapy on plaque
volume (however with no significant changes in lumen vol-
ume), external elastic membrane, fibrous and dense cal-
cium volumes, while fibro-fatty and necrotic core tissue
volumes remained statistically unchanged.
The potential reason for obtaining these results may
lie in the fact that foam cells function as a substrate for
the progression of necrosis [31]. The existence of foam
cells and non-load-bearing lipid pools enzymatic to-
gether with destruction of collagen by matrix metallo-
proteinases, and microcalcifications might produce a
TCFA, increasing the risk of plaque rupture and MACE
[32]. However, statins have been associated with increase
in fibrous cap thickness in optical coherence tomog-
raphy (OCT) studies [33]. In these OCT studies, only
assessment of the near field can be achieved due to the
poor penetration of the technology and therefore the
quantification of fibrous tissue in the total plaque cannot
be obtained. In our meta-analysis that included only
VH-IVUS studies, we observed a global decrease in fi-
brous tissue associated with statin treatment. In other
words, there may be two differential effects of statin
treatment, on the one hand a focal increase in cap thick-
ness and on the other hand a global decrease in fibrous
tissue. This hypothesis needs further investigation.
Increased quantities of calcium in coronary plaques have
been linked to negative remodeling [34, 35], in contrast to
increased lipid and fibro-fatty elements usually seen in
positively remodeled lesions [36, 37]. Moreover, ACS and
histological features of plaque vulnerability such as a large
lipid core and high macrophage content seems to be asso-
ciated with a positive coronary arterial remodeling [38].
Many studies such as the Myocardial Ischemia Reduction
with Aggressive Cholesterol Lowering (MIRACL) [39] and
the Pravastatin or Atorvastatin Evaluation and Infection
Therapy–Thrombolysis in Myocardial Infarction 22
(PROVE IT-TIMI 22) [40] have reported that intensive
statin therapy reduces MACE in patients with coronary
heart disease. Significant plaque burden, extensive re-
modeling and calcification have been regarded as funda-
mental morphologies of high-risk plaques leading to
MACE [41]. It has been shown that statin therapy im-
proves plaque hyperechogenicity without a considerable
decrease in plaque volume, suggesting that statins might
influence coronary artery plaque composition [42].
Moreover, in non-culprit, high-risk coronary lesions after
the onset of ACS, statins proved to be beneficial for re-
gression and stabilization of vulnerable plaques [41].
However, the effect of statin therapy on plaque vol-
ume and composition might essentially differ by sta-
tin preparations, doses, duration of therapy, methods
of imaging, as well as plaque localization. In the Re-
versal of Atherosclerosis with Aggressive Lipid Low-
ering (REVERSAL) trial [43], moderate lipid-lowering
therapy with 40 mg of pravastatin did not stop plaque pro-
gression, while treatment with 80 mg of atorvastatin
did. The first study showing reduction on plaque size
was the a Study to Evaluate the Effect of Rosuvastatin
on Intravascular Ultrasound-Derived Coronary Atheroma
Burden (ASTEROID) trial with 40 mg of rosuvastatin [44].
However, these trials have only evaluated quantitative
changes of coronary artery plaque using gray-scale IVUS
and did not study plaque composition changes. Our meta-
analysis showed that statin therapy reduces atheroma
plaque volume, however with no significant changes in
lumen volume. It also influences plaque composition re-
ducing fibrous volume, however with no significant
changes in fibro-fatty and necrotic core tissue volumes.
Although these results differed between available studies
Fig. 8 Funnel plot detailing publication bias in the studies reporting the impact of statin therapy on plaque volume. Open circles represent
observed published studies; closed circles represent imputed unpublished studies
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[14, 21–28], these observations confirm the changes in
plaque composition affecting lesion size and plaque sta-
bility (changes the composition of plaques from fatty to
fibrous). On the other hand, the lack of effect on nec-
rotic material is highly concerning for the field, given
that the outcome studies in this field have largely sup-
ported the findings that TCFA is associated with ad-
verse outcomes [45].
Statin therapy induced a significant regression of IVUS-
measured coronary plaque volume, especially when reach-
ing the target LDL-C level, as shown in a meta-analysis of
gray-scale IVUS studies investigating temporal modifica-
tions in coronary plaque volume [46]. However, conven-
tional gray-scale IVUS compared with VH-IVUS method
has many limitations in the evaluation of atheromatous
plaque composition and identification of a vulnerable
plaque prior to rupture [47–49]. Another study indicated
that VH-IVUS may potentially allow the best detection of
features associated with future plaque rupture, increasing
the probability of superior risk stratification at the moment
of percutaneous coronary intervention [50].
The present meta-analysis has several limitations.
Most importantly, there were few eligible prospective
trials, and most had small numbers of patients. Further-
more, the included studies were heterogeneous regard-
ing factors such as population characteristics (different
statins, doses and duration of treatment), study design
and VH-IVUS methodology (for example, in some of the
included studies VH-IVUS was not performed in all pa-
tients and there were different IVUS catheters used in
the included studies). There were only two studies con-
trolled with placebo, and others compared high-intensity
versus moderate/low-intensity statin therapy. Further-
more, VH-IVUS was only performed in one coronary
vessel, which might not reflect changes in plaque fea-
tures sampled from other regions of the coronary tree.
Plaque volume might be also very variable when measured
in mm3 across studies. Finally, the use of serial VH-IVUS
imaging might be problematic, as it is ECG gated, so there
is limited ability to precisely match segments.
Conclusions
In conclusion, this meta-analysis of nine prospective stud-
ies comprising 16 statin-treated arms indicates a significant
effect of statin therapy on plaque, external elastic mem-
brane, fibrous and dense calcium volumes, while fibro-fatty
and necrotic core tissue volumes remained statistically un-
changed. Further large-scale, well-designed head-to-head
trials are warranted to fully address the differential effects
on these parameters with different statins.
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